Docetaxel liposomal - Insys Therapeutics

Drug Profile

Docetaxel liposomal - Insys Therapeutics

Alternative Names: LE-DT; Liposome encapsulated docetaxel - Insys Therapeutics; Liposome entrapped docetaxel - Insys Therapeutics

Latest Information Update: 19 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NeoPharm Inc
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pancreatic cancer; Prostate cancer

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 31 Dec 2011 NeoPharm Inc completes a phase II trial in Pancreatic cancer in USA (NCT01186731)
  • 01 Jun 2010 Phase-II clinical trials in metastatic, castrate resistant Prostate cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top